GlassScriptPhysician profile
Charles D Dillon
NPI 1548273568
$2,648.58
in general payments reported to CMS, 2019-2025
30 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $236 · 2023: $174 · 2024: $417 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $266.27 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $258.13 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $237.06 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $158.41 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.92 | 2019-2020 | |
| Exact Sciences Corporation | $147.56 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $141.05 | 2024-2025 | |
| Cleerly, INC. | $86.39 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Lilly USA, LLC | $85.99 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $74.45 | 2019-2025 | Gardasil 9, Capvaxive |
| Corcept Therapeutics | $66.94 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $63.56 | 2024-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $49.81 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.01 | 2019-2020 | |
| Braintree Laboratories, INC. | $36.64 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.91 | 2023 | Rexulti |
| Ironwood Pharmaceuticals, INC | $24.61 | 2019-2020 | |
| Seqirus USA INC | $24.30 | 2025 | Flucelvax, Fluad |
| Ars Pharmaceuticals Operations, INC. | $24.05 | 2025 | Neffy |
| Horizon Therapeutics Plc | $21.81 | 2023 | Krystexxa |
| Astellas Pharma US INC | $21.11 | 2024 | Veozah |
| Genentech USA, INC. | $20.83 | 2019 | |
| Sanofi Pasteur INC. | $19.33 | 2019 | |
| Alfasigma USA, INC. | $18.26 | 2020 | |
| Shire North American Group INC | $15.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.54 | 2019 | |
| Bausch Health US, LLC | $14.41 | 2019 | |
| Metuchen Pharmaceuticals | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.